Literature DB >> 21734364

Telomeres in trisomy 21 amniocytes.

R Sukenik-Halevy1, T Biron-Shental, R Sharony, M D Fejgin, A Amiel.   

Abstract

Individuals with trisomy 21 have an increased risk of developing leukemia and premature dementia. They also have a higher rate of telomere loss. The aim of the study was to compare telomere length and the hTERC gene copy number, which encodes the telomerase RNA subunit, in amniocytes of trisomy 21 conceptions and normal pregnancies. A quantitative fluorescence-in-situ protocol (Q-FISH) was used to compare telomere length in amniocytes cultured from 11 trisomy 21 conceptions and from 14 normal pregnancies. Quantification was conducted using novel computer software. Fluorescence in situ hybridization (FISH) was used to assess the percentage of cells with additional copies of hTERC. We found that the immunofluorescence intensity, which represents telomere length, was significantly lower in amniocytes from trisomy 21 conceptions compared to the control group. The trisomy 21 group had a higher number of cells with additional copies of hTERC. This observation could be one of the cytogenetic parameters that represent a state of genetic instability and might play a role in the pathomechanism of typical features of Down syndrome, such as dementia and malignancy.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21734364     DOI: 10.1159/000329714

Source DB:  PubMed          Journal:  Cytogenet Genome Res        ISSN: 1424-8581            Impact factor:   1.636


  5 in total

1.  Telomere shortening in Down syndrome patients--when does it start?

Authors:  Aleksandra Gruszecka; Przemysław Kopczyński; Dorota Cudziło; Natalia Lipińska; Aleksandra Romaniuk; Wojciech Barczak; Natalia Rozwadowska; Ewa Totoń; Błażej Rubiś
Journal:  DNA Cell Biol       Date:  2015-03-18       Impact factor: 3.311

2.  Peripheral blood telomere alterations in ground glass opacity (GGO) lesions may suggest malignancy.

Authors:  Matthew Koslow; David Shitrit; Lilach Israeli-Shani; Orit Uziel; Einat Beery; Alexandra Osadchy; Yael Refaely; Gali Epstein Shochet; Aliza Amiel
Journal:  Thorac Cancer       Date:  2019-03-12       Impact factor: 3.500

3.  Challenges and Opportunities for Translation of Therapies to Improve Cognition in Down Syndrome.

Authors:  Sarah E Lee; Monica Duran-Martinez; Sabina Khantsis; Diana W Bianchi; Faycal Guedj
Journal:  Trends Mol Med       Date:  2019-11-07       Impact factor: 11.951

4.  An Integrated Human/Murine Transcriptome and Pathway Approach To Identify Prenatal Treatments For Down Syndrome.

Authors:  Faycal Guedj; Jeroen LA Pennings; Lauren J Massingham; Heather C Wick; Ashley E Siegel; Umadevi Tantravahi; Diana W Bianchi
Journal:  Sci Rep       Date:  2016-09-02       Impact factor: 4.379

5.  Reduced placental telomere length during pregnancies complicated by intrauterine growth restriction.

Authors:  Jérôme Toutain; Martina Prochazkova-Carlotti; David Cappellen; Ana Jarne; Edith Chevret; Jacky Ferrer; Yamina Idrissi; Fanny Pelluard; Dominique Carles; Brigitte Maugey-Laulon; Didier Lacombe; Jacques Horovitz; Jean-Philippe Merlio; Robert Saura
Journal:  PLoS One       Date:  2013-01-11       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.